FarmaKology Newsletter - Issue #69
Force Therapeutics is a powerful, episode-based digital care platform and research network designed to help clinicians intelligently extend their reach. Our platform leverages video and digital connections to directly engage patients at every step of their journey - from the point that surgery is scheduled, to post-op and beyond. Backed by the insights of more than 60 leading healthcare centres in the country, the Force Therapeutics platform is proven to drive more effective recovery, lower costs, and achieve better patient outcomes.
Formycon AG and Leukocare AG today announced a collaboration in the area of high-quality biopharmaceuticals. Under the terms of this agreement, Leukocare will apply its formulation development technologies combining state-of-the-art protein analytics, bioinformatics and artificial intelligence to develop stable formulations potentially for several candidates in Formycon´s product pipeline.
Revive Therapeutics Ltd., a speciality life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the Thermo Scientific AerosolSense Sampler, a new surveillance solution designed to deliver fast and highly reliable insight into the presence of in-air pathogens, including SARS-CoV-2. Enables decision-makers in hospitals and other facilities to take actions to protect their employees and provide the public with confidence.
Valence Discovery, an emerging leader in AI-enabled drug design, announced today a multi-target discovery collaboration leveraging Valence’s platform for generative drug design with Servier, a global pharmaceutical company.